Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 113

1.

Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis.

Ellenberger D, Eichstädt K, Flachenecker P, Friede T, Haas J, Kleinschnitz C, Pöhlau D, Rienhoff O, Stahmann A, Zettl UK, Rommer PS.

Mult Scler Relat Disord. 2018 Jul 24;25:173-174. doi: 10.1016/j.msard.2018.07.040. [Epub ahead of print] No abstract available.

PMID:
30096682
2.

Applying the 2017 McDonald diagnostic criteria for multiple sclerosis.

Rommer PS, Zettl UK.

Lancet Neurol. 2018 Jun;17(6):497-498. doi: 10.1016/S1474-4422(18)30161-3. No abstract available.

PMID:
29778357
3.

Coping behavior in multiple sclerosis-complementary and alternative medicine: A cross-sectional study.

Rommer PS, König N, Sühnel A, Zettl UK.

CNS Neurosci Ther. 2018 Apr 10. doi: 10.1111/cns.12857. [Epub ahead of print]

4.

Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis.

Mueller SH, Färber A, Prüss H, Melzer N, Golombeck KS, Kümpfel T, Thaler F, Elisak M, Lewerenz J, Kaufmann M, Sühs KW, Ringelstein M, Kellinghaus C, Bien CG, Kraft A, Zettl UK, Ehrlich S, Handreka R, Rostásy K, Then Bergh F, Faiss JH, Lieb W, Franke A, Kuhlenbäumer G, Wandinger KP, Leypoldt F; German Network for Research on Autoimmune Encephalitis (GENERATE).

Ann Neurol. 2018 Apr;83(4):863-869. doi: 10.1002/ana.25216.

PMID:
29572931
5.

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.

Graetz C, Gröger A, Luessi F, Salmen A, Zöller D, Schultz J, Siller N, Fleischer V, Bellenberg B, Berthele A, Biberacher V, Havla J, Hecker M, Hohlfeld R, Infante-Duarte C, Kirschke JS, Kümpfel T, Linker R, Paul F, Pfeuffer S, Sämann P, Toenges G, Weber F, Zettl UK, Jahn-Eimermacher A, Antony G, Groppa S, Wiendl H, Hemmer B, Mühlau M, Lukas C, Gold R, Lill CM, Zipp F.

Mult Scler. 2018 Mar 1:1352458518763541. doi: 10.1177/1352458518763541. [Epub ahead of print]

PMID:
29532745
6.

Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.

Rommer PS, Zettl UK.

Expert Opin Pharmacother. 2018 Apr;19(5):483-498. doi: 10.1080/14656566.2018.1446944. Epub 2018 Mar 12. Review.

PMID:
29528247
7.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

8.

Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome.

Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, Rejdak K, Evdoshenko E, Makshakov G, Nazarov V, Lapin S, Midaglia L, Vidal-Jordana A, Drulovic J, García-Merino A, Sánchez-López AJ, Havrdova E, Saiz A, Llufriu S, Alvarez-Lafuente R, Schroeder I, Zettl UK, Galimberti D, Ramió-Torrentà L, Robles R, Quintana E, Hegen H, Deisenhammer F, Río J, Tintoré M, Sánchez A, Montalban X, Comabella M.

Brain. 2018 Apr 1;141(4):1085-1093. doi: 10.1093/brain/awy021.

PMID:
29452342
9.

Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.

Angerer IC, Hecker M, Koczan D, Roch L, Friess J, Rüge A, Fitzner B, Boxberger N, Schröder I, Flechtner K, Thiesen HJ, Winkelmann A, Meister S, Zettl UK.

CNS Neurosci Ther. 2018 Mar;24(3):193-201. doi: 10.1111/cns.12793. Epub 2018 Jan 3.

PMID:
29314605
10.

Headache in the first manifestation of Multiple Sclerosis - Prospective, multicenter study.

Gebhardt M, Kropp P, Jürgens TP, Hoffmann F, Zettl UK.

Brain Behav. 2017 Nov 16;7(12):e00852. doi: 10.1002/brb3.852. eCollection 2017 Dec.

11.

Information processing deficits as a driving force for memory impairment in MS: A cross--sectional study of memory functions and MRI in early and late stage MS.

Köhler W, Fischer M, Bublak P, Faiss JH, Hoffmann F, Kunkel A, Sailer M, Schwab M, Stadler E, Zettl UK, Penner IK; HIPPOCOMS Study Group.

Mult Scler Relat Disord. 2017 Nov;18:119-127. doi: 10.1016/j.msard.2017.09.026. Epub 2017 Sep 25.

PMID:
29141793
12.

NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.

Malhotra S, Sorosina M, Río J, Peroni S, Midaglia L, Villar LM, Álvarez-Cermeño JC, Schroeder I, Esposito F, Clarelli F, Zettl UK, Lechner-Scott J, Spataro N, Navarro A, Comi G, Montalban X, Martinelli-Boneschi F, Comabella M.

Mult Scler. 2017 Nov 1:1352458517739137. doi: 10.1177/1352458517739137. [Epub ahead of print]

13.

Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients-A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness.

Ehler J, Blechinger S, Rommer PS, Koball S, Mitzner S, Hartung HP, Leutmezer F, Sauer M, Zettl UK.

Int J Mol Sci. 2017 Aug 11;18(8). pii: E1749. doi: 10.3390/ijms18081749.

14.

CSF profile in primary progressive multiple sclerosis: Re-exploring the basics.

Abdelhak A, Hottenrott T, Mayer C, Hintereder G, Zettl UK, Stich O, Tumani H.

PLoS One. 2017 Aug 10;12(8):e0182647. doi: 10.1371/journal.pone.0182647. eCollection 2017.

15.

Spasticity in multiple sclerosis: Contribution of inflammation, autoimmune mediated neuronal damage and therapeutic interventions.

Patejdl R, Zettl UK.

Autoimmun Rev. 2017 Sep;16(9):925-936. doi: 10.1016/j.autrev.2017.07.004. Epub 2017 Jul 8. Review.

PMID:
28698092
16.

The Development of Sayk's Cell Sedimentation Chamber: A Historical View on Clinical Cerebrospinal Fluid Diagnostics.

Dahlmann N, Zettl UK, Kumbier E.

Eur Neurol. 2017;77(3-4):162-167. doi: 10.1159/000456003. Epub 2017 Jan 25.

17.

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.

Berger T, Elovaara I, Fredrikson S, McGuigan C, Moiola L, Myhr KM, Oreja-Guevara C, Stoliarov I, Zettl UK.

CNS Drugs. 2017 Jan;31(1):33-50. doi: 10.1007/s40263-016-0394-8. Review.

18.

Hans Queckenstedt (1876-1918).

Kumbier E, Zettl UK.

J Neurol. 2017 May;264(5):1032-1034. doi: 10.1007/s00415-016-8315-9. Epub 2016 Oct 19. No abstract available.

PMID:
27761642
19.

Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.

Huss AM, Halbgebauer S, Öckl P, Trebst C, Spreer A, Borisow N, Harrer A, Brecht I, Balint B, Stich O, Schlegel S, Retzlaff N, Winkelmann A, Roesler R, Lauda F, Yildiz Ö, Voß E, Muche R, Rauer S, Bergh FT, Otto M, Paul F, Wildemann B, Kraus J, Ruprecht K, Stangel M, Buttmann M, Zettl UK, Tumani H.

J Neurol. 2016 Dec;263(12):2499-2504. Epub 2016 Oct 11.

20.

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation.

Andlauer TF, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, Chan A, Gasperi C, Gold R, Graetz C, Haas J, Hecker M, Infante-Duarte C, Knop M, Kümpfel T, Limmroth V, Linker RA, Loleit V, Luessi F, Meuth SG, Mühlau M, Nischwitz S, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Arloth J, Weber P, Radivojkov-Blagojevic M, Scheinhardt MO, Dankowski T, Bettecken T, Lichtner P, Czamara D, Carrillo-Roa T, Binder EB, Berger K, Bertram L, Franke A, Gieger C, Herms S, Homuth G, Ising M, Jöckel KH, Kacprowski T, Kloiber S, Laudes M, Lieb W, Lill CM, Lucae S, Meitinger T, Moebus S, Müller-Nurasyid M, Nöthen MM, Petersmann A, Rawal R, Schminke U, Strauch K, Völzke H, Waldenberger M, Wellmann J, Porcu E, Mulas A, Pitzalis M, Sidore C, Zara I, Cucca F, Zoledziewska M, Ziegler A, Hemmer B, Müller-Myhsok B.

Sci Adv. 2016 Jun 17;2(6):e1501678. doi: 10.1126/sciadv.1501678. eCollection 2016 Jun.

Supplemental Content

Loading ...
Support Center